Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

NextEdge Admin

19 Nov 2024

2 min 14 sec

FDA approval,companion diagnostic,lung cancer

Foundation Medicine, Inc. has announced FDA approval for its FoundationOne®Liquid CDx as a companion diagnostic for TEPMETKO® (tepotinib), developed by EMD Serono, the healthcare business of Merck KGaA in Darmstadt, Germany. TEPMETKO received FDA accelerated approval in 2021 and traditional approval in February 2024 for treating adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations (METex14). FoundationOne Liquid CDx is the first FDA-approved liquid biopsy to identify patients eligible for TEPMETKO.

NSCLC accounts for approximately 85% of lung cancers, with 3–4% associated with METex14 alterations, which are linked to advanced disease and poor prognosis. FoundationOne Liquid CDx analyzes over 300 cancer-related genes from a routine blood sample, enabling comprehensive genomic profiling.

“This approval highlights the critical role of high-quality liquid biopsies in expanding precision medicine access,” said Mia Levy, M.D., Ph.D., Chief Medical Officer at Foundation Medicine. “Our test empowers clinicians to identify more patients with METex14 alterations for targeted treatment.”

Foundation Medicine leads in FDA-approved companion diagnostic indications, offering the most robust portfolio for NSCLC. The company has 19 FDA-approved indications for NSCLC and 50% of all NGS-based approvals in the U.S. and Japan.

Laurie Ambrose, CEO of GO2 for Lung Cancer, emphasized the significance of biomarker testing in making advanced treatments accessible, praising the role of non-invasive liquid biopsies in enhancing patient care.